Polaryx Therapeutics, Inc. Cash & Equivalents decreased by 40.1% to $3.08M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase signals improved liquidity and financial flexibility, while a decrease may indicate heavy capital expenditure, debt repayment, or aggressive share buybacks.
Represents the most liquid assets on the balance sheet, including physical currency and short-term investments with matu...
Large-cap technology peers often maintain high cash balances to fund rapid innovation and offset the cyclical nature of consumer electronics.
cash_and_equivalents| Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $250.00K | $5.14M | $3.08M |
| QoQ Change | — | >999% | -40.1% |
| YoY Change | — | — | >999% |